[⁸⁹Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models.

"Competing Interests: James M. Markert has the following relationships which may pose or be perceived as posing a financial conflict of interest. He is a board and equity holding member, in Aettis, Inc. and may receive royalties. The company holds frozen oncolytic viral stocks. Mustang Bio Tech is licensing the IP of C134 an oncolytic viral therapy. Markert is blinded to the conditions for the C134 clinical trials. He is a shareholder for this privately held Small Business Innovation Research LLC, Treovir, Inc., concerning G207 oncolytic viral therapy now in clinical trial. Merck, Inc. provides industry grant support by providing Keytruda (pembrolizumab) for a clinical trial of M032 oncolytic virotherapy now in clinical trial. Markert is a listee on Intellectual Property, related to a cancer immunotherapy system filed by in8Bio, formerly Incysus, Ltd. This IP has royalty earning potential."

"Funding This work was supported by NCI R01CA279143-01 and R01CA240589 and UAB internal research gift (Markert). The authors would also like to thank UAB's Small Animal Imaging Facility through the O'Neal Comprehensive Cancer Center (Grant number: P30CA013148). This work was also supported by UAB's cyclotron facility and UAB's pathology core. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32EB023872 and T32GM135028. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."